CAS: 5704-03-0; [(8R,9S,10R,13S,14S,17S)-10,13-Dimethyl-3-Oxo-1,2,6,7,8,9,11,12,14,15,16,17-Dodecahydrocyclopenta[a]Phenanthren-17-Yl] 2-Phenylacetate

上下游产品

CAS号58-22-0 睾酮 | CAS号103-80-0 苯乙酰氯

📜睾酮,苯乙酰氯置于吡啶,苯体系中,化学反应生成 苯乙酸睾酮
参考文献:The Tectonic Uplift Of The Hua Shan In The Cenozoic
标题:The Tectonic Uplift Of The Hua Shan In The Cenozoic
摘要:Six Granite Samples Were Collected From Six Difference Elevation Locations At The Hua Shan In A Main Ridge Of The Qinling Mountain. Apatite And Zircon Separated From These Six Samples Were Dated By The Fission Track Technique. An Assessment Of The Cenozoic Uplift Or Exhumation Rate Was Obtained From The Altitude Difference Of Sampling Samples Dated By Fission Track,And From The Difference Of Fission Track Dates Of Both Apatite And Zircon For A Sample. The Preliminary Results Suggest That The Beginning Of Uplift Of The Hua Shan Was As Early As 68.2 Mabp And The Uplift Rates For Different Periods Are 0.02-0.19 Mm/a (From The Elevation Difference) Or 0.12-0.16 Mm/a (From Two Mineral Fission Track Dates). The Average Uplift Rate Is 0.12 Mm/a (From The Elevation Difference) Or 0.14 Mm/a (From Two Mineral Fission Track Dates). The Uplift Of The Hua Shan Might Accelerate Since (17.8 +/-2.0) Mabp,And The Average Uplift Rate Is About 0.19 Mm/a.
DOI:10.1007/bf02900632

专利信息

专利号:US-2025281509-A1
优先权日:2021-04-26
标 题 :Sequential hormone therapy to improve survival and enhance response to immune therapy in men with prostate cancer
发明人：DENMEADE SAMUEL R; ISAACS JOHN T; ANTONARAKIS EMMANUEL S; KACHHAP SUSHANT; MARKOWSKI MARK CHRISTOPHER
权利人:UNIV JOHNS HOPKINS
摘要:Disclosed are methods for treating men with castrate resistant prostate cancer with a sufficient dose of testosterone to achieve supraphysiologic serum levels of testosterone in sequence with androgen ablative treatment or androgen synthesis inhibitors for one or more cycles until evidence of radiographic progression, at which point the subject will receive immune checkpoint blockade therapy.